Sue Siegel brings extensive expertise to enterprises, having served as a CEO, venture capitalist, and board director in the life sciences and healthcare industries. As a board director, she has served on public and private corporate boards across big and small companies and for nonprofit organizations. She is a visionary leader known for identifying and seizing transformative opportunities that help organizations create returns for shareholders, build new markets, and impact lives. Siegel is recognized as a builder of ultra-high-performing teams and directs her energies toward unlocking untapped potential in individuals and across teams to drive growth.

Over more than 20 years, Siegel has served on more than 20 public and private company boards as well as at nonprofit organizations. Her current board portfolio includes Align Technology, Illumina, Nevro Corp., and KFF (formerly the Kaiser Family Foundation), and she is chair of the board of The Engine Accelerator, built by MIT. Siegel has served on a range of board committees spanning audit, compensation, nominating and governance, technology, investment, and special, several of which she has served as chair. She has been named one of the most influential leaders in corporate governance by NACD as part of its 2023 and 2024 NACD Directorship 100™.

Siegel’s public service includes having served on President Barack Obama’s working group for starting the Precision Medicine Initiative, which led to the creation of All of US; as a founding board member of the National Center for Advancing Translational Sciences; and as a selection judge for White House fellows across administrations. She served on the nonprofit boards of the National Venture Capital Association and Silicon Valley’s The Tech Interactive.

She currently co-chairs Stanford Medicine’s board of fellows and is a member of the innovation growth board of Mass General Brigham and its innovator development and growth division. During her business career, Siegel served as GE’s chief innovation officer, CEO of GE ventures and licensing, and CEO of Healthymagination. Prior to that, she was a venture capital general partner at Mohr Davidow Ventures, leading investments in precision health and life sciences. During the early days of the human genome project, Siegel led Affymetrix, one of the fastest-growing, Silicon Valley–based genomics companies of its time. She drove its growth from a pre-revenue startup to a multibillion-dollar Nasdaq-listed company that helped shape the emerging genomics industry, including addressing emerging bioethical issues. She is also currently on the faculty at the MIT Sloan School of Management.

Siegel has been recognized among Fortune’s “34 Leaders Who Are Changing Health Care,” as one of Silicon Valley Business Journal’s “The 100 Most Influential Women in Silicon Valley,” and among Fierce Biotech’s “Top 10 Women in Medical Devices,” and she was awarded the Lifetime Achievement Award by Global Corporate Venturing in 2020. She was selected as an Aspen Institute Henry Crown Fellow and is a featured “multiplier” in the bestselling book Multipliers: How the Best Leaders Make Everyone Smarter.